Sugammadex + Neostigmine + Glycopyrrolate + Rocuronium
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Spine Surgery
Conditions
Spine Surgery, Reversal of Neuromuscular Blockade, Urinary Retention Postoperative
Trial Timeline
Aug 3, 2023 → Jun 1, 2026
NCT ID
NCT05887375About Sugammadex + Neostigmine + Glycopyrrolate + Rocuronium
Sugammadex + Neostigmine + Glycopyrrolate + Rocuronium is a approved stage product being developed by Merck for Spine Surgery. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05887375. Target conditions include Spine Surgery, Reversal of Neuromuscular Blockade, Urinary Retention Postoperative.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05887375 | Approved | Recruiting |
Competing Products
2 competing products in Spine Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| sugammadex + Neostigmine | Merck | Approved | 85 |
| Dexmedetomidine + Normal Saline | Pfizer | Pre-clinical | 22 |